MDCXW — Medicus Pharma Ltd.
—
Nasdaq ·
Health Care ·
Pharmaceuticals ·
CIK 1997296 ·
Last close
—
Market Cap
—
52W High
—
52W Low
—
ADV30
—
Next earnings
—
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | Gross profit | Op income | Net income | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Jun 2026 | 0 | — | -11,478,789 | -11,617,705 | 27,116,185 | 15,174,128 | 28,841,149 |
| Mar 2026 | 0 | — | -8,597,077 | -9,042,143 | 7,426,911 | 6,365,624 | 5,999,017 |
| Dec 2025 | 0 | — | -7,790,600 | -8,184,411 | 10,061,377 | 8,705,218 | 10,024,066 |
| Sep 2025 | 0 | — | -15,426,340 | -15,981,312 | 9,977,661 | 8,662,091 | 10,782,551 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-27,805,463
Investing CF
$0
Financing CF
$35,005,835
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
—
As of
2026-08-16
Balance + Analyst (yfinance extras)
Retained Earnings
$-73,390,261
Inventory
—
Receivables
$14,000
ST Investments
—
EBIT TTM
$-37,900,627
Pretax Income TTM
$-39,384,264
Interest Exp TTM
$1,170,822
Analysts
—
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | Op income | Net income | Assets | Liabilities | Equity | Op cash flow |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -34,359,302 | -35,444,215 | 10,061,377 | 10,024,066 | -67,554 | -22,776,769 |
| Dec 2024 | 0 | -11,180,902 | -11,155,516 | 5,646,878 | 2,512,174 | 3,134,704 | -10,247,231 |
| Dec 2023 | 0 | -2,658,365 | -5,314,765 | 1,893,057 | 781,609 | 1,111,448 | -4,158,264 |
| Dec 2022 | 0 | -978,416 | -1,692,382 | 282,652 | 12,480,684 | -12,198,032 | -1,057,103 |
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.06T | $1183.46 | — |
| JNJ | JOHNSON & JOHNSON | $653.61B | $271.22 | — |
| ABBV | AbbVie Inc. | $467.12B | $264.34 | — |
| MRK | Merck & Co., Inc. | $367.07B | $148.78 | — |
| NVS | NOVARTIS AG | $276.48B | $145.46 | — |
News headlines (Yahoo Finance, 1h cache)
Medicus Pharma to focus SkinJect development exclusively on Gorlin syndrome patients
2026-09-21 13:50 · Yahoo
Medicus Pharma Optimizes Portfolio Strategy With High-Value Focus
2026-09-21 11:32 · Yahoo
Medicus Pharma Announces Exclusive Development Focus for SkinJect® in Gorlin Syndrome Following Commercial, Clinical and Regulatory Assessment
2026-09-21 11:30 · Yahoo
What Is Pfizer (PFE) Really Getting From Its New ADC Licensing Deal?
2026-09-16 00:19 · Yahoo
Medicus Pharma CEO on SkinJect and Pfizer partnership – ICYMI
2026-09-12 14:32 · Yahoo
Medicus Pharma secures Pfizer ADC deal, advances SkinJect and precision oncology strategy
2026-09-10 15:58 · Yahoo
Medicus Pharma Identifies 200 µg SkinJect Patch as Lead Development Dose After Phase 2 Study
2026-09-10 14:38 · Yahoo
Medicus Pharma reports positive Phase 2 data for SkinJect in skin cancer treatment
2026-09-10 13:45 · Yahoo
Medicus Pharma Publishes Abridged Final Phase 2 SkinJect® Clinical Study Report (CSR) Results Identifying 200 µg D-MNA Patch as the Lead Development Dose
2026-09-10 11:30 · Yahoo
Dow closes sharply lower as oil surge fuels inflation fears
2026-09-08 14:10 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.